News & Updates

The oral selective inhibitor of exportin-1 (XPO1) selinexor has therapeutic potential in recurrent glioblastoma, yielding favourable responses and clinically relevant 6-month progression-free survival (PFS) rate with manageable side effects requiring dose reductions, according to the results of a phase II trial.

The addition of mogamulizumab to nivolumab falls short of improving efficacy of the latter in the treatment of patients with locally advanced or metastatic solid tumours, according to the results of a phase I/II trial.

Giving adjuvant S-1 to patients with curatively resected biliary tract cancer (BTC) significantly improves survival compared with observation following surgery, according to the ASCOT trial presented in the 2022 ASCO Gastrointestinal Cancers Symposium (GICS).

Continuous exposure to radiation during cancer therapy promotes ulceration of tissues or radionecrosis, and a recent study revealed that the use of low-level light therapy may accelerate the resolution of skin damage by up to 50 percent.

The addition of postoperative radiotherapy (PORT) or postoperative concurrent chemoradiotherapy (POCRT) to surgery led to significant improvements in disease-free survival (DFS) and overall survival (OS) in individuals with pathological stage IIB-III oesophageal squamous cell carcinoma (SCC) compared with surgery alone, a prospective phase III study from China suggests.